Heparin resistance in acute coronary syndromes
Maintaining a therapeutic level of anticoagulation with unfractionated heparin remains a major challenge for clinicians because of the wide variability of patient responses, which may be explained by variable binding of heparin to plasma proteins. Direct thrombin inhibitors may offer an advantage in more predictable anticoagulation.
Plasma samples from normal volunteers, stable coronary artery disease (CAD) patients, unstable angina patients, and acute myocardial infarction patients were obtained. A fixed concentration of heparin (.13 U/ml) or bivalirudin (1.6 μg/ml) was added to plasma from each of the four study groups and measurement of the APTT was performed. In addition, a pool of plasma from patients with acute MI was diluted in pooled normal plasma, and heparin or bivalirudin was added to the plasma preparation and APTT measurements performed.
In heparin-treated plasma samples, mean APTT values were 443 ± 137% baseline for normal volunteers, 347 ± 116% for patients with stable CAD, 290 ± 124% for patients with unstable angina (p < 0.05), and 230 ± 120% for patients with acute MI (p < 0.05). APTT did not differ across the four groups treated with bivalirudin. There was a much higher degree of variability in APTT values in heparin treated controls (272%–671%, SD ∼30%) compared to bivalirudin treated controls (284–499%, SD ∼12%). When the “acute MI pool” was diluted in pooled normal plasma at fixed concentrations of either bivalirudin (1.6 μg/ml) or heparin (0.13 U/ml), there was a sharp decrease in heparin activity from 407% baseline (at 0% acute MI pool) to values as low as 126% baseline (at 100% acute MI pool). A markedly different pattern was seen in the bivalirudin treated samples, where a trend towards decreased APTT values was seen only at the 100% acute MI pool.
Both heparin variability and resistance may limit optimal antithrombotic therapy with heparin in patients with ACS and constitutes a potential advantage of direct antithrombin blockade with bivalirudin.
KeywordsAnticoagulation Heparin Resistance
- 2.Young E, Prins M, Levine MN, Hirsh J (1992) Heparin binding to plasma proteins, an important mechanism for heparin resistance. Thromb Haemostasis 67(6):639–643Google Scholar
- 5.Young E, Wells P, Holloway S, Weitz J, Hirsh J (1994) Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thrombosis Haemostasis 71(3):300–304Google Scholar
- 6.Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, Lopez-Sendon JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E (2006) Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. The New England J Med 354(14):1477–1488CrossRefGoogle Scholar
- 9.Ferguson JJ (1995) Recent advances in the treatment of acute myocardial infarction. Texas Heart Inst J/Texas Heart Inst St 22(1):26–32Google Scholar
- 10.Fox I, Dawson A, Loynds P, Eisner J, Findlen K, Levin E, Hanson D, Mant T, Wagner J, Maraganore J (1993) Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans. Thromb Haemostasis 69(2):157–163Google Scholar
- 12.A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The global use of strategies to open occluded coronary arteries (GUSTO) IIb investigators. The New England J Med 335(11):775–782 (1996)Google Scholar
- 17.Young E, Podor TJ, Venner T, Hirsh J (1997) Induction of the acute-phase reaction increases heparin-binding proteins in plasma. Arteriosclerosis Thromb Vascular Biol 17(8):1568–1574Google Scholar
- 18.Casu B, Oreste P, Torri G, Zoppetti G, Choay J, Lormeau JC, Petitou M, Sinay P (1981) The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem J 197(3):599–609PubMedGoogle Scholar
- 23.Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M (1994) A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Int Med 154(1):49–56CrossRefGoogle Scholar
- 24.Becker RC, Ball SP, Eisenberg P, Borzak S, Held AC, Spencer F, Voyce SJ, Jesse R, Hendel R, Ma Y, Hurley T, Hebert J (1999) A randomized, multicenter trial of weight-adjusted intravenous heparin dose titration and point-of-care coagulation monitoring in hospitalized patients with active thromboembolic disease. Antithrombotic Therapy Consortium Investigators. Am Heart J 137(1):59–71PubMedCrossRefGoogle Scholar
- 26.Kroon C, ten Hove WR, de Boer A, Kroon JM, van der Pol JM, Harthoorn-Lasthuizen EJ, Schoemaker HC, van der Meer FJ, Cohen AF (1992) Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Circulation 86(5):1370–1375PubMedGoogle Scholar
- 29.Cloyd GM, D’Ambra MN, Akins CW (1987) Diminished anticoagulant response to heparin in patients undergoing coronary artery bypass grafting. The J Thoracic Cardiovas Surgery 94(4):535–538Google Scholar
- 30.Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC (1983) Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment. The J Thoracic Cardiovas Surgery 85(3):346–353Google Scholar
- 33.International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 97(24):2386–2395 (1998)Google Scholar
- 34.Newby LK, Harrington RA, Bhapkar MV, Van de Werf F, Hochman JS, Granger CB, Simes RJ, Davis CG, Topol EJ, Califf RM, Moliterno DJ (2002) An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. J Thromb Thrombolysis 14(1):33–42PubMedCrossRefGoogle Scholar